Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head Injuries, Penetrating | 7 | 2023 | 54 | 1.850 |
Why?
|
Wounds, Gunshot | 3 | 2020 | 71 | 1.020 |
Why?
|
Craniotomy | 2 | 2020 | 88 | 0.870 |
Why?
|
tau Proteins | 6 | 2009 | 62 | 0.840 |
Why?
|
Papilloma, Inverted | 1 | 2020 | 6 | 0.760 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2020 | 24 | 0.740 |
Why?
|
Brain Neoplasms | 6 | 2016 | 763 | 0.730 |
Why?
|
Fasciitis | 1 | 2019 | 10 | 0.720 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2020 | 100 | 0.720 |
Why?
|
Orbital Diseases | 1 | 2019 | 21 | 0.700 |
Why?
|
Brain Diseases | 1 | 2019 | 180 | 0.650 |
Why?
|
Neurosurgical Procedures | 5 | 2023 | 213 | 0.650 |
Why?
|
Glioma | 3 | 2016 | 285 | 0.590 |
Why?
|
Central Nervous System Neoplasms | 2 | 2018 | 81 | 0.580 |
Why?
|
Cerebrospinal Fluid Leak | 1 | 2016 | 10 | 0.560 |
Why?
|
Meningitis | 1 | 2016 | 20 | 0.560 |
Why?
|
Intraoperative Complications | 1 | 2016 | 183 | 0.500 |
Why?
|
Streptavidin | 1 | 2013 | 14 | 0.460 |
Why?
|
Antigens, CD20 | 1 | 2013 | 36 | 0.460 |
Why?
|
Ferric Compounds | 1 | 2013 | 37 | 0.440 |
Why?
|
Endoscopy | 1 | 2016 | 331 | 0.430 |
Why?
|
Lymphoma, B-Cell | 1 | 2013 | 103 | 0.420 |
Why?
|
Brain | 4 | 2020 | 2211 | 0.410 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 555 | 0.390 |
Why?
|
Antibodies | 1 | 2013 | 349 | 0.390 |
Why?
|
Brain Injuries, Traumatic | 2 | 2022 | 86 | 0.360 |
Why?
|
Protein Processing, Post-Translational | 4 | 2008 | 371 | 0.340 |
Why?
|
Biopsy | 1 | 2013 | 1160 | 0.340 |
Why?
|
Neurofibrillary Tangles | 3 | 2008 | 45 | 0.340 |
Why?
|
Otolaryngology | 2 | 2022 | 53 | 0.340 |
Why?
|
Alzheimer Disease | 4 | 2008 | 470 | 0.310 |
Why?
|
Peptide Fragments | 2 | 2006 | 460 | 0.300 |
Why?
|
Skull Base | 4 | 2022 | 47 | 0.280 |
Why?
|
Pituitary Neoplasms | 2 | 2016 | 62 | 0.280 |
Why?
|
Postoperative Complications | 1 | 2016 | 2183 | 0.270 |
Why?
|
Humans | 31 | 2023 | 86281 | 0.260 |
Why?
|
Caspases | 1 | 2004 | 155 | 0.250 |
Why?
|
Meningioma | 2 | 2016 | 60 | 0.240 |
Why?
|
Patient Satisfaction | 2 | 2022 | 452 | 0.200 |
Why?
|
Ambulatory Care Facilities | 1 | 2022 | 102 | 0.200 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 503 | 0.200 |
Why?
|
Gene Rearrangement | 2 | 2019 | 170 | 0.200 |
Why?
|
Brain Injuries | 1 | 2023 | 160 | 0.190 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 567 | 0.190 |
Why?
|
Injury Severity Score | 1 | 2021 | 111 | 0.190 |
Why?
|
Hemangioma, Cavernous, Central Nervous System | 1 | 2023 | 223 | 0.180 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 63 | 0.180 |
Why?
|
Gene Fusion | 1 | 2019 | 38 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 2594 | 0.180 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2019 | 25 | 0.180 |
Why?
|
Myosin Heavy Chains | 1 | 2019 | 88 | 0.180 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 63 | 0.170 |
Why?
|
Drainage | 1 | 2020 | 157 | 0.170 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 119 | 0.170 |
Why?
|
Cranial Fossa, Posterior | 1 | 2018 | 25 | 0.170 |
Why?
|
Cranial Fossa, Middle | 1 | 2018 | 11 | 0.170 |
Why?
|
Telemedicine | 1 | 2021 | 168 | 0.170 |
Why?
|
Tissue and Organ Procurement | 1 | 2022 | 310 | 0.160 |
Why?
|
Skull | 1 | 2020 | 248 | 0.160 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 1168 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 3347 | 0.150 |
Why?
|
Seizures | 1 | 2020 | 293 | 0.150 |
Why?
|
Chromosomes, Human | 1 | 2016 | 66 | 0.140 |
Why?
|
Professional Corporations | 1 | 2016 | 1 | 0.140 |
Why?
|
Oncogene Proteins v-myb | 1 | 2016 | 3 | 0.140 |
Why?
|
Lymphoma | 1 | 2018 | 262 | 0.140 |
Why?
|
Cranial Nerve Diseases | 1 | 2016 | 7 | 0.140 |
Why?
|
Male | 9 | 2023 | 40860 | 0.140 |
Why?
|
Proto-Oncogene Proteins | 2 | 2013 | 645 | 0.140 |
Why?
|
Middle Aged | 5 | 2023 | 24957 | 0.130 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 61 | 0.130 |
Why?
|
Child | 4 | 2022 | 6913 | 0.130 |
Why?
|
Nose | 1 | 2016 | 94 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 128 | 0.130 |
Why?
|
Extracellular Matrix Proteins | 1 | 2015 | 123 | 0.120 |
Why?
|
Precision Medicine | 2 | 2016 | 394 | 0.120 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 244 | 0.120 |
Why?
|
Glasgow Coma Scale | 2 | 2023 | 65 | 0.120 |
Why?
|
Tissue Engineering | 1 | 2015 | 181 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2013 | 60 | 0.110 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2013 | 114 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2015 | 415 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 321 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 739 | 0.100 |
Why?
|
Trans-Activators | 1 | 2013 | 429 | 0.090 |
Why?
|
Mutation | 6 | 2016 | 3952 | 0.090 |
Why?
|
Female | 7 | 2023 | 44405 | 0.090 |
Why?
|
Amino Acid Sequence | 3 | 2009 | 2062 | 0.090 |
Why?
|
Cohort Studies | 3 | 2021 | 2759 | 0.090 |
Why?
|
Antibody Specificity | 2 | 2008 | 129 | 0.080 |
Why?
|
Gliosis | 1 | 2008 | 35 | 0.080 |
Why?
|
Adult | 5 | 2023 | 25577 | 0.080 |
Why?
|
Nitrates | 1 | 2008 | 35 | 0.080 |
Why?
|
Protein Folding | 1 | 2009 | 280 | 0.080 |
Why?
|
Astrocytes | 1 | 2008 | 139 | 0.080 |
Why?
|
Epitopes | 2 | 2004 | 255 | 0.070 |
Why?
|
Aminopeptidases | 1 | 2006 | 17 | 0.070 |
Why?
|
Arachidonic Acid | 1 | 2006 | 63 | 0.070 |
Why?
|
Algorithms | 1 | 2015 | 1828 | 0.070 |
Why?
|
Protein Conformation | 2 | 2006 | 881 | 0.070 |
Why?
|
Recombinant Proteins | 2 | 2006 | 1014 | 0.070 |
Why?
|
Disease Progression | 2 | 2015 | 1531 | 0.070 |
Why?
|
Molecular Sequence Data | 2 | 2009 | 3029 | 0.070 |
Why?
|
Exome | 2 | 2016 | 127 | 0.070 |
Why?
|
Caspase 6 | 1 | 2004 | 2 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 2004 | 24 | 0.060 |
Why?
|
Comparative Genomic Hybridization | 2 | 2016 | 39 | 0.060 |
Why?
|
src-Family Kinases | 1 | 2004 | 74 | 0.060 |
Why?
|
Single-Blind Method | 1 | 2004 | 151 | 0.060 |
Why?
|
Retrospective Studies | 3 | 2023 | 8431 | 0.060 |
Why?
|
Kinetics | 1 | 2006 | 1513 | 0.060 |
Why?
|
Binding Sites | 1 | 2006 | 1098 | 0.060 |
Why?
|
Neurotoxins | 1 | 2003 | 49 | 0.060 |
Why?
|
Temporal Lobe | 1 | 2004 | 172 | 0.060 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 2351 | 0.060 |
Why?
|
Amino Acid Substitution | 1 | 2004 | 339 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2016 | 6481 | 0.060 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 424 | 0.060 |
Why?
|
Intracranial Pressure | 1 | 2023 | 77 | 0.060 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 53 | 0.050 |
Why?
|
Death | 1 | 2023 | 72 | 0.050 |
Why?
|
Amyloid beta-Peptides | 1 | 2003 | 203 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2016 | 455 | 0.050 |
Why?
|
Antibodies, Monoclonal | 2 | 2008 | 1376 | 0.050 |
Why?
|
Models, Molecular | 1 | 2006 | 1284 | 0.050 |
Why?
|
Receptors, Drug | 1 | 2001 | 54 | 0.050 |
Why?
|
Resuscitation | 1 | 2022 | 100 | 0.050 |
Why?
|
Pheochromocytoma | 1 | 2001 | 49 | 0.050 |
Why?
|
Monitoring, Physiologic | 1 | 2023 | 268 | 0.050 |
Why?
|
Office Visits | 1 | 2021 | 44 | 0.050 |
Why?
|
Hemorrhage | 1 | 2023 | 265 | 0.050 |
Why?
|
Patient Participation | 1 | 2023 | 216 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2016 | 1196 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 222 | 0.050 |
Why?
|
Protein Kinase C | 1 | 2001 | 270 | 0.050 |
Why?
|
Neoplasms | 1 | 2015 | 2889 | 0.050 |
Why?
|
Young Adult | 2 | 2023 | 5961 | 0.050 |
Why?
|
Length of Stay | 1 | 2023 | 697 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2023 | 373 | 0.050 |
Why?
|
Spinal Injuries | 1 | 2020 | 22 | 0.050 |
Why?
|
Hematologic Diseases | 1 | 2020 | 79 | 0.040 |
Why?
|
Craniocerebral Trauma | 1 | 2020 | 52 | 0.040 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 69 | 0.040 |
Why?
|
Patient Selection | 1 | 2023 | 685 | 0.040 |
Why?
|
Vascular Diseases | 1 | 2020 | 119 | 0.040 |
Why?
|
Survivors | 1 | 2020 | 225 | 0.040 |
Why?
|
Intracranial Aneurysm | 1 | 2020 | 158 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 2421 | 0.040 |
Why?
|
Apoptosis | 1 | 2004 | 1678 | 0.040 |
Why?
|
Steroids | 1 | 2018 | 172 | 0.040 |
Why?
|
INDEL Mutation | 1 | 2016 | 30 | 0.040 |
Why?
|
Aged | 3 | 2016 | 18353 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2023 | 3616 | 0.030 |
Why?
|
Neurons | 1 | 2004 | 1545 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2015 | 62 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 171 | 0.030 |
Why?
|
Incidence | 1 | 2020 | 1568 | 0.030 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2015 | 135 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 104 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2015 | 103 | 0.030 |
Why?
|
Biomarkers | 1 | 2021 | 1709 | 0.030 |
Why?
|
Carcinogenesis | 1 | 2016 | 194 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 266 | 0.030 |
Why?
|
3T3 Cells | 1 | 2013 | 94 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 526 | 0.030 |
Why?
|
Smoothened Receptor | 1 | 2013 | 6 | 0.030 |
Why?
|
Enzyme Activation | 2 | 2006 | 692 | 0.030 |
Why?
|
Neurofibromin 2 | 1 | 2013 | 30 | 0.030 |
Why?
|
PC12 Cells | 2 | 2003 | 115 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2015 | 912 | 0.030 |
Why?
|
Machine Learning | 1 | 2015 | 232 | 0.030 |
Why?
|
Multigene Family | 1 | 2013 | 202 | 0.030 |
Why?
|
Prospective Studies | 1 | 2021 | 4194 | 0.030 |
Why?
|
Risk Assessment | 1 | 2020 | 2253 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2015 | 589 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2015 | 530 | 0.030 |
Why?
|
Blotting, Western | 2 | 2004 | 781 | 0.030 |
Why?
|
Genome, Human | 1 | 2016 | 756 | 0.030 |
Why?
|
Mice, Nude | 1 | 2013 | 790 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 736 | 0.020 |
Why?
|
Adolescent | 1 | 2023 | 8968 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 1671 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 853 | 0.020 |
Why?
|
Alleles | 1 | 2013 | 1127 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 1381 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2009 | 269 | 0.020 |
Why?
|
Base Sequence | 1 | 2013 | 2329 | 0.020 |
Why?
|
Genetic Variation | 1 | 2015 | 1349 | 0.020 |
Why?
|
Alternative Splicing | 1 | 2009 | 201 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2008 | 58 | 0.020 |
Why?
|
Plaque, Amyloid | 1 | 2008 | 56 | 0.020 |
Why?
|
Tyrosine | 1 | 2008 | 133 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 1611 | 0.020 |
Why?
|
Genomics | 1 | 2013 | 710 | 0.020 |
Why?
|
Puromycin | 1 | 2006 | 10 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2020 | 7949 | 0.020 |
Why?
|
Rats | 2 | 2003 | 3984 | 0.020 |
Why?
|
Child, Preschool | 1 | 2013 | 3608 | 0.020 |
Why?
|
Postmortem Changes | 1 | 2004 | 8 | 0.020 |
Why?
|
Aspartic Acid | 1 | 2004 | 64 | 0.020 |
Why?
|
Signal Transduction | 1 | 2015 | 3233 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 314 | 0.020 |
Why?
|
Nitroblue Tetrazolium | 1 | 2003 | 2 | 0.020 |
Why?
|
Ginkgo biloba | 1 | 2003 | 5 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2008 | 1752 | 0.010 |
Why?
|
Diffusion | 1 | 2003 | 93 | 0.010 |
Why?
|
Antigens | 1 | 2004 | 228 | 0.010 |
Why?
|
Gene Deletion | 1 | 2004 | 328 | 0.010 |
Why?
|
Body Temperature | 1 | 2003 | 124 | 0.010 |
Why?
|
Animals | 3 | 2013 | 26518 | 0.010 |
Why?
|
Neuroprotective Agents | 1 | 2003 | 94 | 0.010 |
Why?
|
Ligands | 1 | 2003 | 433 | 0.010 |
Why?
|
Imidazoline Receptors | 1 | 2001 | 2 | 0.010 |
Why?
|
Phosphorylation | 1 | 2004 | 1101 | 0.010 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2001 | 34 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2001 | 108 | 0.010 |
Why?
|
Clonidine | 1 | 2001 | 37 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2001 | 137 | 0.010 |
Why?
|
Plant Extracts | 1 | 2003 | 243 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 113 | 0.010 |
Why?
|
Cell Survival | 1 | 2003 | 966 | 0.010 |
Why?
|
Isoenzymes | 1 | 2001 | 271 | 0.010 |
Why?
|
Imidazoles | 1 | 2001 | 163 | 0.010 |
Why?
|
Cell Division | 1 | 2001 | 696 | 0.010 |
Why?
|
Mice | 1 | 2013 | 11313 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 1748 | 0.010 |
Why?
|